B Cells and Tertiary Lymphoid Structures: Emerging Targets in Cancer Therapeutics

摘要 请求为题为"B细胞和第三类星形结构： 癌症治疗中的新兴靶点，由Tullia Bruno、布拉德纳尔逊、丹尼尔霍伦和 玛丽-卡罗琳·迪厄-诺斯让会议将于2023年10月1日至4日在不列颠哥伦比亚省惠斯勒举行。 随着疫苗、基于抗体的免疫疗法和B细胞功能机制的科学发现， B细胞的研究取得了突破性进展这标志着一个研究领域， 获得知识和有效治疗的增长。特别是，对B细胞生物学的新见解 揭示了疾病中保守的方面;例如，B细胞现在被认为是疾病中的关键参与者。 癌症患者对免疫疗法的反应和癌症患者的严重程度的三级乳突状结构（TLS） 自身免疫性疾病。同样地，B调节细胞使用机制来保护免受自身免疫， 共同的模式，他们燃料癌症的进展和耐药性的治疗。通过检查数据 跨学科，科学家们正在收集主要的见解，塑造了整个领域的进步， research.为了促进B细胞研究领域的突破进程，我们建立了B细胞 在癌症联盟（BC 3）汇集这个不断增长的社区，正如预期的那样，有高 兴趣具体来说，我们的第一年已经建立了一个选区的500多名科学家为我们的虚拟研讨会 系列.鉴于免疫学研究的快速发展，这意味着可能会有更多的观众 受全球流行病的影响。随着mRNA疫苗和单克隆抗体疗法成为高风险的话题， 暴露，人们比以往任何时候都更了解B细胞生物学。本届基石研讨会开幕式 这将是这个新兴领域首次有机会聚集在一起，提供一个独特的机会， 连接和催化未来的研究B细胞功能在癌症中的重要性。

ABSTRACT Support is requested for a Keystone Symposia conference entitled B Cells and Tertiary Lymphoid Structures: Emerging Targets in Cancer Therapeutics, organized by Drs. Tullia Bruno, Brad Nelson, Daniel Hollern and Marie-Caroline Dieu-Nosjean. The conference will be held in Whistler, British Columbia from October 1-4, 2023. With vaccines, antibody-based immunotherapy, and scientific discoveries of B cell functional mechanisms, major breakthroughs are happening surrounding B cells. This marks a field of research that is poised for exponential growth in acquisition of knowledge and effective therapies. In particular, the novel insights into B cell biology have revealed conserved aspects across disease; for example, B cells are now recognized as critical players in Tertiary Lymphoid Structures (TLS) for both cancer patient response to immunotherapy and the severity of autoimmune disease. Likewise, B regulatory cells use mechanisms to protect from autoimmunity that are common to the mode by which they fuel cancer’s progression and resistance to therapy. By examining data across disciplines, scientists are gleaning major insights that shape the forward progression of the entire field of research. To foster the process of breakthroughs in the field of B cell research, we have established the B Cells in Cancer Consortium (BC3) to bring together this ever-growing community, and as expected, there is high interest. Specifically, our first year has built a constituency of more than 500 scientists for our virtual seminar series. This signifies a likelihood for an even larger audience given the expansive pace of immunology research driven by the global pandemic. With mRNA vaccines and monoclonal antibody therapies being a topic of high exposure, people are more informed than ever on B cell biology. This inaugural Keystone Symposia conference will be the first opportunity for this nascent field to meet together, providing a unique opportunity to forge new connections and catalyze future research into the importance of B cell function in cancer.